A citation-based method for searching scientific literature

Daniel F Martin, Maureen G Maguire, Stuart L Fine, Gui-shuang Ying, Glenn J Jaffe, Juan E Grunwald, Cynthia Toth, Maryann Redford, Frederick L Ferris. Ophthalmology 2012
Times Cited: 1250







List of co-cited articles
642 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Ranibizumab for neovascular age-related macular degeneration.
Philip J Rosenfeld, David M Brown, Jeffrey S Heier, David S Boyer, Peter K Kaiser, Carol Y Chung, Robert Y Kim. N Engl J Med 2006
49

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Jeffrey S Heier, David M Brown, Victor Chong, Jean-Francois Korobelnik, Peter K Kaiser, Quan Dong Nguyen, Bernd Kirchhof, Allen Ho, Yuichiro Ogura, George D Yancopoulos,[...]. Ophthalmology 2012
37

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
David M Brown, Peter K Kaiser, Mark Michels, Gisele Soubrane, Jeffrey S Heier, Robert Y Kim, Judy P Sy, Susan Schneider. N Engl J Med 2006
31

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.
Usha Chakravarthy, Simon P Harding, Chris A Rogers, Susan M Downes, Andrew J Lotery, Lucy A Culliford, Barnaby C Reeves. Lancet 2013
508
27

Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
Daniel F Martin, Maureen G Maguire, Gui-shuang Ying, Juan E Grunwald, Stuart L Fine, Glenn J Jaffe. N Engl J Med 2011
26

Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.
Wan Ling Wong, Xinyi Su, Xiang Li, Chui Ming G Cheung, Ronald Klein, Ching-Yu Cheng, Tien Yin Wong. Lancet Glob Health 2014
25

Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).
Soraya Rofagha, Robert B Bhisitkul, David S Boyer, SriniVas R Sadda, Kang Zhang. Ophthalmology 2013
649
21

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
Ursula Schmidt-Erfurth, Peter K Kaiser, Jean-François Korobelnik, David M Brown, Victor Chong, Quan Dong Nguyen, Allen C Ho, Yuichiro Ogura, Christian Simader, Glenn J Jaffe,[...]. Ophthalmology 2014
521
21

Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials.
Maureen G Maguire, Daniel F Martin, Gui-Shuang Ying, Glenn J Jaffe, Ebenezer Daniel, Juan E Grunwald, Cynthia A Toth, Frederick L Ferris, Stuart L Fine. Ophthalmology 2016
374
18

Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.
Robyn H Guymer, Caroline M Markey, Ian L McAllister, Mark C Gillies, Alex P Hunyor, Jennifer J Arnold. Ophthalmology 2019
132
18


HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Pravin U Dugel, Adrian Koh, Yuichiro Ogura, Glenn J Jaffe, Ursula Schmidt-Erfurth, David M Brown, Andre V Gomes, James Warburton, Andreas Weichselberger, Frank G Holz. Ophthalmology 2020
272
15

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
David M Brown, Mark Michels, Peter K Kaiser, Jeffrey S Heier, Judy P Sy, Tsontcho Ianchulev. Ophthalmology 2009
950
14

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
Usha Chakravarthy, Simon P Harding, Chris A Rogers, Susan M Downes, Andrew J Lotery, Sarah Wordsworth, Barnaby C Reeves. Ophthalmology 2012
585
13

A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Geeta A Lalwani, Philip J Rosenfeld, Anne E Fung, Sander R Dubovy, Stephen Michels, William Feuer, Janet L Davis, Harry W Flynn, Maria Esquiabro. Am J Ophthalmol 2009
668
13

Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study.
Rufino Silva, András Berta, Michael Larsen, Wayne Macfadden, Chrystel Feller, Jordi Monés. Ophthalmology 2018
140
13

Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results.
Charles C Wykoff, Daniel E Croft, David M Brown, Rui Wang, John F Payne, Lloyd Clark, Nizar Saleh Abdelfattah, SriniVas R Sadda. Ophthalmology 2015
180
13

Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration.
Frank G Holz, Ramin Tadayoni, Stephen Beatty, Alan Berger, Matteo G Cereda, Rafael Cortez, Carel B Hoyng, Philip Hykin, Giovanni Staurenghi, Stephanie Heldner,[...]. Br J Ophthalmol 2015
340
12

Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).
Ursula Schmidt-Erfurth, Victor Chong, Anat Loewenstein, Michael Larsen, Eric Souied, Reinier Schlingemann, Bora Eldem, Jordi Monés, Gisbert Richard, Francesco Bandello. Br J Ophthalmol 2014
308
12

Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials.
Juan E Grunwald, Ebenezer Daniel, Jiayan Huang, Gui-Shuang Ying, Maureen G Maguire, Cynthia A Toth, Glenn J Jaffe, Stuart L Fine, Barbara Blodi, Michael L Klein,[...]. Ophthalmology 2014
356
11

Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials.
Juan E Grunwald, Maxwell Pistilli, Ebenezer Daniel, Gui-Shuang Ying, Wei Pan, Glenn J Jaffe, Cynthia A Toth, Stephanie A Hagstrom, Maureen G Maguire, Daniel F Martin. Ophthalmology 2017
116
11

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Brandon G Busbee, Allen C Ho, David M Brown, Jeffrey S Heier, Ivan J Suñer, Zhengrong Li, Roman G Rubio, Phillip Lai. Ophthalmology 2013
339
11

Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Allen C Ho, Brandon G Busbee, Carl D Regillo, Mark R Wieland, Sherri A Van Everen, Zhengrong Li, Roman G Rubio, Phillip Lai. Ophthalmology 2014
210
9


Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.
Gui-shuang Ying, Jiayan Huang, Maureen G Maguire, Glenn J Jaffe, Juan E Grunwald, Cynthia Toth, Ebenezer Daniel, Michael Klein, Dante Pieramici, John Wells,[...]. Ophthalmology 2013
215
9

Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.
Glenn J Jaffe, Daniel F Martin, Cynthia A Toth, Ebenezer Daniel, Maureen G Maguire, Gui-Shuang Ying, Juan E Grunwald, Jiayan Huang. Ophthalmology 2013
175
9

Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
Sumit Sharma, Cynthia A Toth, Ebenezer Daniel, Juan E Grunwald, Maureen G Maguire, Gui-Shuang Ying, Jiayan Huang, Daniel F Martin, Glenn J Jaffe. Ophthalmology 2016
132
9

Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study.
Frank G Holz, Winfried Amoaku, Juan Donate, Robyn H Guymer, Ulrich Kellner, Reinier O Schlingemann, Andreas Weichselberger, Giovanni Staurenghi. Ophthalmology 2011
289
8

HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration.
Michael A Singer, Carl C Awh, SriniVas Sadda, William R Freeman, Andrew N Antoszyk, Pamela Wong, Lisa Tuomi. Ophthalmology 2012
261
8

Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Mark C Gillies, Alex P Hunyor, Jennifer J Arnold, Robyn H Guymer, Sebastian Wolf, Paul Ng, Francois L Pecheur, Ian L McAllister. JAMA Ophthalmol 2019
64
12

Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group.
Richard F Spaide, Glenn J Jaffe, David Sarraf, K Bailey Freund, Srinivas R Sadda, Giovanni Staurenghi, Nadia K Waheed, Usha Chakravarthy, Philip J Rosenfeld, Frank G Holz,[...]. Ophthalmology 2020
169
8

The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis.
Tien Y Wong, Usha Chakravarthy, Ronald Klein, Paul Mitchell, Gergana Zlateva, Ronald Buggage, Kyle Fahrbach, Corey Probst, Isabella Sledge. Ophthalmology 2008
388
8

Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
Christian Simader, Markus Ritter, Matthias Bolz, Gabor G Deák, Ulrike Mayr-Sponer, Isabelle Golbaz, Michael Kundi, Ursula M Schmidt-Erfurth. Ophthalmology 2014
117
8

A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration.
Ursula Schmidt-Erfurth, Sebastian M Waldstein. Prog Retin Eye Res 2016
175
8

The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial.
Peter A Campochiaro, Dennis M Marcus, Carl C Awh, Carl Regillo, Anthony P Adamis, Vladimir Bantseev, Yawen Chiang, Jason S Ehrlich, Signe Erickson, William D Hanley,[...]. Ophthalmology 2019
113
8

Age-related macular degeneration.
Paul Mitchell, Gerald Liew, Bamini Gopinath, Tien Y Wong. Lancet 2018
428
8

Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials.
Glenn J Jaffe, Gui-Shuang Ying, Cynthia A Toth, Ebenezer Daniel, Juan E Grunwald, Daniel F Martin, Maureen G Maguire. Ophthalmology 2019
95
8

Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
Mark C Gillies, Anna Campain, Daniel Barthelmes, Judy M Simpson, Jennifer J Arnold, Robyn H Guymer, Ian L McAllister, Rohan W Essex, Nigel Morlet, Alex P Hunyor. Ophthalmology 2015
154
7

Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
SriniVas R Sadda, Lisa L Tuomi, Beiying Ding, Anne E Fung, J Jill Hopkins. Ophthalmology 2018
74
9

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.
Carl D Regillo, David M Brown, Prema Abraham, Huibin Yue, Tsontcho Ianchulev, Susan Schneider, Naveed Shams. Am J Ophthalmol 2008
626
7




Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
Laurent Kodjikian, Eric H Souied, Gérard Mimoun, Martine Mauget-Faÿsse, Francine Behar-Cohen, Evelyne Decullier, Laure Huot, Gilles Aulagner. Ophthalmology 2013
184
7

Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future.
Johanna M Colijn, Gabriëlle H S Buitendijk, Elena Prokofyeva, Dalila Alves, Maria L Cachulo, Anthony P Khawaja, Audrey Cougnard-Gregoire, Bénédicte M J Merle, Christina Korb, Maja G Erke,[...]. Ophthalmology 2017
201
7

Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results.
Karina Berg, Emina Hadzalic, Inger Gjertsen, Vegard Forsaa, Lars Haakon Berger, Bettina Kinge, Hans Henschien, Kristian Fossen, Slavica Markovic, Terje R Pedersen,[...]. Ophthalmology 2016
107
7

Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
Emily Li, Simone Donati, Kristina B Lindsley, Magdalena G Krzystolik, Gianni Virgili. Cochrane Database Syst Rev 2020
32
21

Prevalence of age-related macular degeneration in the United States.
David S Friedman, Benita J O'Colmain, Beatriz Muñoz, Sandra C Tomany, Cathy McCarty, Paulus T V M de Jong, Barbara Nemesure, Paul Mitchell, John Kempen. Arch Ophthalmol 2004
6

Novel method for analyzing snellen visual acuity measurements.
Ninel Z Gregori, William Feuer, Philip J Rosenfeld. Retina 2010
312
6

Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.
Ursula Schmidt-Erfurth, Bora Eldem, Robyn Guymer, Jean-François Korobelnik, Reinier O Schlingemann, Ruth Axer-Siegel, Peter Wiedemann, Christian Simader, Margarita Gekkieva, Andreas Weichselberger. Ophthalmology 2011
287
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.